Wednesday, November 29, 2017 10:16:12 AM
5 minutes ago - DJNF
WALTHAM, Mass.--(BUSINESS WIRE)--November 29, 2017--
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell(R) device usability by improving performance for users that maintain an active lifestyle.
"We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is correlated with better results. The technology in this patent helps Quell meet the needs of even the most active users," said Shai N. Gozani, M.D., Ph.D.
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a clinical study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
New York Yankees and Duke Basketball
Recent NURO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:43:12 PM
- NeuroMetrix Announces Steps Taken to Enhance Shareholder Value • GlobeNewswire Inc. • 04/19/2024 12:00:00 PM
- NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy • GlobeNewswire Inc. • 03/14/2024 01:00:00 PM
- NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia • GlobeNewswire Inc. • 03/13/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:23:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:21:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:20:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:19:11 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:12:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/01/2024 10:07:47 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/27/2024 09:45:07 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/27/2024 09:00:09 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/26/2024 10:41:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:15:08 PM
- NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 07:49:16 PM
- NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call • GlobeNewswire Inc. • 02/15/2024 02:00:00 PM
- NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID) • GlobeNewswire Inc. • 12/12/2023 02:00:00 PM
- NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) • GlobeNewswire Inc. • 12/05/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 02:33:08 PM
- NeuroMetrix Announces One-for-Eight Reverse Stock Split • GlobeNewswire Inc. • 11/20/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:20:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 11:11:44 AM
- NeuroMetrix Reports Q3 2023 Business Highlights • GlobeNewswire Inc. • 10/26/2023 11:00:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM